Skip to main content
Premium Trial:

Request an Annual Quote

Tempus xE Whole-Exome Tumor Sequencing

Personalized cancer technology company Tempus has introduced Tempus xE, a whole-exome sequencing panel that analyzes tumor DNA alongside a normal sample and a whole-RNA transcriptome. The new CLIA/CAP-validated assay gives researchers and clinicians a broad view of potential tumor mutations and treatment pathways, Tempus said. 

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.